Compare the best online tirzepatide providers in 2026 — Ro, Eden, Yucca Health, Willow, Sesame — against the PlexusDx Tirzepatide Injection ($229–$309/mo) and Tirzepatide Oral ($229–$509/mo) Protocols, with a genetic baseline option no other provider offers.

Medicare Part D is statutorily prohibited from covering GLP-1s prescribed solely for weight loss, and manufacturer copay cards are off-limits to Medicare beneficiaries. This guide explains the Medicare GLP-1 Bridge launching July 2026, Part D backdoors for diabetes, CVD, and OSA, and the cash-pay options that work today — including PlexusDx Microdose GLP-1 Protocol at $129/mo flat and Semaglutide Injection at $179–$229/mo.

How PlexusDx Weight Management Protocols compare to the major cash-pay GLP-1 programs in 2026 — Mochi, Eden, MEDVi, Ro, GoodRx Care Direct, NovoCare, and LillyDirect — on price, medication source, membership fees, and total annualized cost.

Compounded tirzepatide provider rankings cycle through MEDVi, Eden, Yucca Health, Willow, and Trim RX. PlexusDx Tirzepatide Injection ($229–$309/mo) and Tirzepatide Oral ($229–$509/mo) compare on price, oversight, and genetic-test personalization.

A buyer-side read of the seven brand-name GLP-1 telehealth providers (Ro, Walgreens, GoodRx, Hims & Hers, PlushCare, Sesame, WeightWatchers) covering true month-one cost, what each dispenses, and how PlexusDx compounded protocols ($129–$325/mo, all-inclusive, no membership) fit when branded coverage isn't accessible.

Zepbound (tirzepatide) is the first FDA-approved medication for obstructive sleep apnea in adults with obesity — approved December 2024 based on the SURMOUNT-OSA trial. This article covers the weight-mediated mechanism, who may benefit, class-wide safety warnings, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape every GLP-1 response.

Zepbound (tirzepatide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Zepbound list price is approximately $1,059 per month at U.S. list price as of April 2026 (Eli Lilly published pricing). This article covers manufacturer savings programs, insurance coverage notes, compounded alternatives, and the PlexusDx Weight Management Protocols collection — all as of April 2026.

Wegovy (semaglutide) and Zepbound (tirzepatide) are widely compared GLP-1 pathway compounds. This head-to-head covers mechanism, FDA status, trial evidence, boxed-warning safety, April 2026 list pricing, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape baseline GLP-1 biology.

Zepbound is a GLP-1 pathway compound relevant to weight management through its effects on appetite, satiety, and metabolism. This article covers mechanism, clinical trial evidence, FDA-approved indications, boxed-warning safety, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape every GLP-1 response.

Wegovy (semaglutide) and Zepbound (tirzepatide) are widely compared GLP-1 pathway compounds. This head-to-head covers mechanism, FDA status, trial evidence, boxed-warning safety, April 2026 list pricing, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape baseline GLP-1 biology.

"zepbound vs tirzepatide" is typically a disambiguation question about brand name and active ingredient. This article explains the relationship, why one molecule has multiple brand names, how insurance coverage is assigned at the product level, and how PlexusDx fits into the compounded-alternative space.

"tirzepatide vs zepbound" is typically a disambiguation question about brand name and active ingredient. This article explains the relationship, why one molecule has multiple brand names, how insurance coverage is assigned at the product level, and how PlexusDx fits into the compounded-alternative space.

No FDA-approved generic Zepbound exists as of April 2026. This article explains why (patent exclusivity and the biosimilar pathway), what "generic Zepbound" typically means in consumer search, legitimate compounded alternatives through licensed pharmacies, and PlexusDx Weight Management Protocols as a published-price option.

Zepbound is Eli Lilly's tirzepatide brand for chronic weight management (2023) and obstructive sleep apnea (2024) — it is NOT FDA-approved for type 2 diabetes. Mounjaro is the same molecule separately approved for diabetes. This article explains the brand distinction, April 2026 cost, and the FTO, GLP1R, TCF7L2, and MC4R genetic architecture.

Zepbound is Eli Lilly's brand name for tirzepatide — the same GIP/GLP-1 dual agonist active ingredient as Mounjaro, but labeled for chronic weight management (2023) and obstructive sleep apnea (2024). This article covers the brand-vs-drug-name relationship, FDA indications, April 2026 pricing, and the FTO/GLP1R/MC4R genetic architecture underneath.

Ozempic (semaglutide) and Zepbound (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Microdose GLP-1 protocols use lower-than-standard doses of GLP-1 receptor agonists titrated by a clinician for better tolerability. This article covers what microdose means, the rationale, and the PlexusDx Microdose GLP-1 protocol inside the Weight Management Protocols collection.

Zepbound (tirzepatide) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. This article covers SURMOUNT-OSA trial outcomes, mechanism, safety, and the GLP-1 pathway genetics.

Zepbound (tirzepatide) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. This article covers SURMOUNT-OSA trial outcomes, mechanism, safety, and the GLP-1 pathway genetics.

Zepbound list price is approximately $1,059 per month at U.S. list price as of April 2026 (Eli Lilly published pricing). This article covers manufacturer savings programs, insurance coverage notes, compounded alternatives, and the PlexusDx Weight Management Protocols collection — all as of April 2026.

Zepbound (tirzepatide) and Mounjaro (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Mounjaro (tirzepatide) and Zepbound (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Zepbound (tirzepatide) and Ozempic (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Zepbound (tirzepatide) and Wegovy (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Wegovy (semaglutide) and Zepbound (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Zepbound (tirzepatide) has an FDA-approved dosing structure with graduated titration. This article covers the label-level dose range, administration format, and titration concept — clinical decisions belong with a qualified healthcare provider.

Zepbound list price is approximately $1,059 per month at U.S. list price as of April 2026 (Eli Lilly published pricing). This article covers manufacturer savings programs, insurance coverage notes, compounded alternatives, and the PlexusDx Weight Management Protocols collection — all as of April 2026.